Inviting the Media to Life Sciences Summit 2011

Interested in bringing novel therapeutics to patients? Want to discuss more efficient ways to develop drugs?

Then the Life Sciences Summit 2011 was the conference for you.

Held in New York last week, the conference was a forum for key opinion leaders from industry, academia, medical research foundations and other major stakeholders to explore new paradigms of drug development, examine barriers to success and to discuss strategies for improving efficiency and productivity in therapeutic development.

Russo Partners’ objective was to raise awareness of the conference in the media community, a task we were happy to undertake.

Our first step was to develop a media advisory describing the event, as well as potential sources in attendance, and then to distribute the document to select media contacts. Russo Partners continued working to facilitate connections between the media and attendees, both in advance of and during the conference.

We are pleased to report that the conference was well attended by both media and companies alike, and we are looking forward to assisting Life Sciences Summit in their media outreach next year.

Introducing OrbusNeich’s Combo (TM) Dual Therapy Stent

Press conference for OrbusNeich's late-breaking data

Last week in a late breaking session at Transcatheter Cardiovascular Therapeutics (TCT) 2011, OrbusNeich presented data for the company’s first-of-its-kind Combo Dual Therapy Stent, which combines a drug elution with the pro-healing healing GenousTM technology.

While the current standard of care for patients with coronary artery disease, drug eluting stents (DES), have reduced the risk of restenosis (narrowing of the artery), even the most advanced DES can cause delayed healing. The Combo Dual Therapy Stent is the first dual therapy stent to offer the best of both worlds, a stent combining pro-healing technology with a drug elution.

Data from the REMEDEE (Randomized Evaluation of an abluMinal sirolimus coatED bioEngineered stEnt) trial demonstrated the safety and efficacy of the dual therapy stent (DTS) compared to a clinically proven DES. The primary end point of the study was in-stent late lumen loss at nine months, which is the difference in diameter of the stented area before and after the procedure.

Russo Partners was on-site in San Francisco to support and maximize awareness of OrbusNeich’s data announcement in the medical community. Our efforts included securing and coordinating in-person media interviews as well as the use of social media, utilizing Twitter to alert followers to OrbusNeich’s news releases and presentations.

We are excited by this promising data and the potential benefits it has for patients, and we are looking forward to additional data announcements from OrbusNeich when we can continue to provide guidance as well as support for their communications activities.

Below are examples of coverage generated from the data announcement:

Medical Device Daily

MedPage Today

Media Relations: The Importance of Dialogue

A cornerstone of our media relations philosophy is to always engage in a dialogue with a journalist, taking the time to find out their specific interests and preferences and to build a strong relationship.

So when we received an opportunity to attend Business Wire’s 50th anniversary event, Meet the Media, featuring an expert panel of local journalists discussing characteristics of effective pitching and current trends in journalism, we had to make sure we were in the audience.

As we expected, it was well worth our time.

The format led to an excellent discussion that ranged from insight about uses of social media to best practices for pitching a story, with actionable steps surrounding each topic. Key points either reinforced what we already knew or brought up interesting points that were not immediately apparent, such as the importance of easily-accessible photos in the increasingly digital age. Each insight re-emphasized our belief that an ongoing dialogue with the media is crucial to be able to work effectively and efficiently together.

We would like to extend a special thanks to the panelists, Keith Darcé, biotechnology writer for The San Diego Union-Tribune, Bruce Bigelow, editor of Xconomy, and Joe Guerin, editor of the San Diego Daily Transcriptas well as moderator Katie Easkins, vice president of Lewis PR, for their time and participation. We hope you found it as helpful as we did!

Ringing the NASDAQ Closing Bell

Two of our Russo Partners team members, Martina Schwarzkopf and Elliot Fox, attended the ringing of the NASDAQ closing bell today, hosted by Amarin (AMRN), a biopharmaceutical company using lipid science to treat cardiovascular disease.

BIO Investor Forum: Supporting Our Clients’ Participation as Panelists, Presenters

Last  week took us to San Francisco for the 10th Annual BIO Investor Forum, an investor conference focused on private and emerging public biotech companies. Multiple clients were involved in the conference either as presenters or panel participants discussing key issues affecting the biotechnology industry. Russo Partners was there to support their activities.

Clients participating on panels included Sutro Biopharma and GlobeImmune. William Newell, chief executive officer of Sutro Biopharma, a company with a biochemical protein synthesis technology platform enabling the design and development of novel proteins that previously have been inaccessible or difficult to produce, provided insight into the future of biosimilars and development strategies on the panel titled Biologics: Billions from BioBetters?

On another panel titled Immunotherapy: Heal Thyself, Timothy Rodell, M.D., president and chief executive officer of GlobeImmune, a company developing therapeutic vaccines for cancer and infectious diseases, discussed the promising future of immunotherapies.

Our clients Anaphore and Flexion Therapeutics also participated in the conference as presenting companies. Brinson Patrick Securities also took advantage of this conference for onsite networking and media opportunities.

At a rich networking event such as BIO Investor Forum, Russo Partners works to maximize our clients’ time spent at the conference by connecting the company executives to key members of the life sciences community.

We look forward to preparing our clients to deliver their “stories” at the next industry event.

Congratulations to Cellular Dynamics International (CDI), Gold Winner of The Wall Street Journal’s 2011 Technology Innovation Awards

Receiving an award is a great way for a company to raise its profile and
gain recognition for its technology or therapeutic. Throughout the year multiple award programs are applicable to our clients, including The Scientist’s Top 10 Innovations, the MIT International Technology Awards and the honor our client CDI received this week, The Wall Street Journal’s 2011 Technology Innovation Gold Award.

Before Russo Partners begins the process of submitting a client for consideration for an award, several criteria must first be met. It is important to understand the award and what is needed in order to be considered. What is the publication looking for? What does a company need to have in order to qualify? This can also be determined by looking at past winners and verifying that the company is similar to others in the category; for instance, you might consider whether a company also has an innovative technology in the vein of a past winner or is comparable in size to one that came before.

Secondly, the award must support the client’s communications objectives. Will this award benefit perception? Is the award credible? An award from The Wall Street Journal or The Scientist is highly regarded by others in the investment and scientific communities and is undoubtedly beneficial for our clients. Receiving an award from a prestigious publication raises awareness and adds validation to the technology or therapeutic being recognized.

As CDI’s recent recognition demonstrates, when all of these pieces are in place, the payoff is certainly worth it.

Below are links to The Wall Street Journal article about the winners, the article profiling CDI and a video describing the winners.

The Wall Street Journal Article About the Winners

The Wall Street Journal Article Profiling CDI

Wall Street Journal Video Describing the Winners

Developing the Company “Story”

Before a company begins a public relations program, it is key that the executives and PR advisors develop the company “story” — the key messaging points the company would like to convey to its target audiences. For life science companies, target audiences may range from investors and potential partners to physicians and patients. However, before delivering a story it is important to first gain key insights from the target audiences.

This is where story development comes into play.

The most efficient way to determine what target audiences understand and value about a company, and what’s not quite clear, is to ask them. At Russo Partners, we have expertise in creating thoughtful and insightful questions designed to elicit perspective from the individuals in each target audience, as well as the executive management team. The questions are specifically tailored to each company and audience with the company’s final objectives in mind.

We quantify and analyze these findings to develop the proposed messages and recommendations for the company’s communications moving forward. These messages are not what we think we should say; instead they are designed to communicate in a manner that properly shape audience mindsets and lead to action — for example, an inquiry from a prospective investor.

The findings are then presented to the client and serve as the basis for discussion and interactive exercises. Key messaging points are finalized and following the workshop we capture the messages in a story checklist, which can be applied to all of the company’s communication tools.

Once a company has developed and identified its “story,” the leadership team can implement their communications program, confident that their key messages will resonate with each audience.

Below is a sample slide displaying results obtained from an investor audience.

Slide displaying sample results

 

Obesity: The Week in Review

If you totaled the number of extra pounds each person in our country weighs, as a whole our nation is 5 billion pounds overweight. It is clear that diet and exercise are not enough to combat the growing epidemic of obesity. Innovative therapeutics and technologies must be developed and pursed in order to treat the numbers of people affected by this condition.

In recognition of this need, obesity was a hot topic this week, as multiple events discussing the use of therapeutics to control this indication were held around the nation.

In New York, a world-renowned authority on hormones, Ronald M. Evans, Ph.D., spoke at a NY Salkexcellerators event about the availability of drugs that could simulate the effect of exercise and reduce muscle wasting. When he is not busy conducting research at the Salk institute about hormones and their functions in normal activities and disease, Dr. Evans enjoys spending time with his daughter, Russo Partners team member Lena Evans.

Further down the coast in Orlando, our client Arena Pharmaceuticals presented at The Obesity Society’s Annual Scientific Meeting. One of the world’s largest gatherings of obesity professionals, leading obesity scientists and clinicians were in attendance to discuss new research findings to help promote treatments for patients with this disease.

With the levels of obesity in our nation growing, we are glad to see that research and therapeutics are under development to help combat the increasing incidence of this disease.

Working like a Company Executive

As our clients know, running a biotechnology company is a fast-paced and extremely busy life. Between the multiple meetings each day, assuring that your investors receive a good return on investment, all while advancing a therapeutic through the clinic, time becomes both limited and extremely valuable.

At Russo Partners, we understand that biotechnology executives are busy people. And we believe that our role is to help as much as possible without getting in the way. Our philosophy is based on the idea that we need to be as dedicated and nimble as the people that we work with.

So are you working in a different time zone and need to send us an email at 3 a.m.? Please do. We will respond as quickly as possible.

Just realized that you need to modify a sentence of a press release the night before it goes out? We’ll take care of the changes and will be up first thing in the morning to make sure the edits went through.

Only have the next few hours in your schedule free for an interview with a journalist? We will work to get you connected and to be there to prep and coordinate the call.

These are only a few examples of how we strive to accommodate the needs of our clients. At Russo Partners, we understand the busy, and sometimes crazy, lives of executives, and we are there to work with you every step of the way.

Raising Awareness of At-The-Market Offerings

What is an at-the-market offering, or ATM? How does it work? How is it beneficial?

Those are the types of questions that Brinson Patrick Securities had heard many times before the investment bank began working with Russo Partners.

While at-the-market (ATM) financing vehicles are an important and efficient way to raise capital over time for a publically traded company, there was not broad awareness of this alternative method of financing in the healthcare business community.

After a detailed analysis of the company and the situation, Russo Partners’ recommended that Brinson Patrick publicize data that quantify the amount of funding raised by life science companies through ATMs on a quarterly basis in the form of a news release. In fact, this data was already collected by Brinson Patrick for internal use, so the exercise proved to be an efficient re-appropriation of already available resources.

Armed with the first quarter news release, Russo Partners reached out to specific media targets at financial publications covering this space. Russo Partners succeeded in securing multiple high-profile opportunities for the company, and, through this process, was able to build awareness of ATMs among members of the media and the healthcare community at large.

On Monday, Brinson Patrick distributed its second news release on the amount of capital raised by life sciences companies through the use of ATM offerings during the second quarter, with the intent to replicate the past media success.

Below are links to the second quarter news release, as well as examples of key coverage we were able to generate with the first quarter news release:

Second Quarter News Release

The Wall Street Journal

The Deal

Xconomy

MedCity News